AveXis, which is developing gene therapies for rare neurological diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Bannockburn, IL-based company was founded in 2010 and plans to list on the Nasdaq under the symbol AVXS. AveXis filed confidentially on October 16, 2015. Goldman Sachs, Jefferies, BMO Capital Markets and Chardan Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
